论文部分内容阅读
目的:评价美托洛尔与曲美他嗪联用对冠心病伴心力衰竭患者的疗效及其对炎症因子和心功能指标的影响。方法:选取2015年3月—2016年11月期间收治的冠心病伴心力衰竭患者80例临床资料,将其随机分为对照组与观察组(每组40例);在常规治疗基础上对照组患者给予美托洛尔片治疗,观察组患者在对照组治疗基础上给予曲美他嗪片治疗,比较两组患者治疗后的疗效及其炎症因子和心功能指标测得值的变化情况。结果:治疗后观察组患者的C反应蛋白(CRP)、脑钠肽(BNP)、左室收缩末期直径(LVESD)和左室舒张末内径(LVEDD)测得值均明显低于对照组(P<0.05),左心射血分数(LVEF)值明显高于对照组(P<0.05)。结论:美托洛尔与曲美他嗪联用治疗冠心病伴心力衰竭患者的疗效优于单用美托洛尔片的疗效,明显改善了其炎症因子及心功能指标值。
OBJECTIVE: To evaluate the efficacy of metoprolol combined with trimetazidine in the treatment of patients with coronary heart disease and heart failure and its effect on inflammatory factors and cardiac function. Methods: Clinical data of 80 patients with coronary heart disease and heart failure admitted from March 2015 to November 2016 were selected and randomly divided into control group and observation group (40 cases in each group). On the basis of routine treatment, the control group The patients were given metoprolol tablets. The patients in the observation group were treated with trimetazidine on the basis of the control group. The curative effect, the changes of inflammatory cytokines and cardiac function indexes in the two groups were compared. Results: After treatment, the levels of CRP, BNP, LVESD and LVEDD in the observation group were significantly lower than those in the control group (P <0.05), LVEF was significantly higher than that of the control group (P <0.05). Conclusion: The combination of metoprolol and trimetazidine is superior to metoprolol alone in the treatment of patients with coronary heart disease and heart failure, and its inflammatory factors and cardiac function indexes are obviously improved.